Acadia Pharmaceuticals(ACAD)

SAN DIEGO, CAPharmaceutical1 H-1B visas (FY2023)

Focus: Acadia Pharmaceuticals is a public specialty pharma company focused on neurology with a small-molecule portfolio. The company is heavily dependent on NUPLAZID, which represents 97% of revenue.

Neurology

Profile data last refreshed 16h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

Should You Work at Acadia Pharmaceuticals?

AI assessment

Acadia is a turnaround-focused specialty pharma with a dominant but aging cash cow and an unproven pipeline—suitable for professionals seeking high stakes, neurology expertise, and commercial-scale impact, but with elevated job security risk.

Why Work Here

Peak revenue product NUPLAZID generated $596M in Part D spending (FY2025) with patent protection until 2037-2039, providing stable base for career development.

Data completeness

7/9 — Strong

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$726M

Key Products

NUPLAZID

Parkinson's Disease Psychosis

$596M Part D

Peak11.1yr

Flagship product generating 97% of company revenue with 12+ years of patent protection remaining; faces generic competition post-LOE.

Help build intelligence for Acadia Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Hiring surge in commercial (18 roles) and data science (6 roles) indicates growth phase investment despite net losses, with recent EU approval of DAYBUE expanding pipeline momentum.

Strong R&D intensity (48%) and Phase 3 pipeline (ACP-204 in Lewy Body Dementia, trofinetide in Rett Syndrome) offer mid-stage drug development exposure.

Watch Out For

Single-product dependency (97% revenue from NUPLAZID) creates existential risk if competitive or regulatory challenges emerge; company posted $61M net loss in FY2025 despite $726M revenue.
Cash position declined to $189M (FY2025) while R&D spending remains ~$350M annually, limiting financial runway if pipeline delays occur; only 1 H1B approval in 2023 suggests constrained hiring appetite for visa sponsorship.

Generated by Claude from Acadia Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

DAYBUE

Rett Syndrome

$19M Part D

Peak16.4yr

Recently approved in EU (June 2026) and US; represents key portfolio diversification with long patent tail until 2043.

DAYBUE STIX

Rett Syndrome

Launch16.4yr

Novel formulation recently launched; early commercialization phase with potential to expand patient uptake in Rett Syndrome.

PIMAVANSERIN

Parkinson's Disease Psychosis (hallucinations and delusions)

Post-LOE

Generic version post-LOE; minimal revenue contribution but maintains market presence in psychosis indication.

Pipeline & Clinical Trials

Real-world non-interventional

Parkinson Disease Psychosis

N/A

Real-world, non-interventional

Parkinson Disease Psychosis

N/A

Clinical Trials (1)

NCT03152292The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study

N/A

Support program

Knee Arthropathy

N/A

Clinical Trials (1)

NCT06575621Knee-hip Surgery Wait-list Support Program

N/A

Virtual reality guided motor rehabilitation

Stroke Acute

N/A

Clinical Trials (1)

NCT06864741Virtual Reality Rehabilitation for Stroke Patients in the Hospital and at Home.

N/A

Observation of minor phenomena

Parkinson Disease

N/A

Clinical Trials (1)

NCT05240339Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)

N/A

ACP-044

Osteoarthritis Pain

Phase 2

Clinical Trials (2)

NCT04855240Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following Bunionectomy

Phase 2

NCT05008835Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee

ACP-103

Hallucinations

Phase 2

Clinical Trials (5)

NCT00658567A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Phase 3

NCT00477672A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

ACP-103

Schizophrenia

Phase 2

Clinical Trials (1)

NCT00361166Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone

Phase 2

ACP-211

Major Depressive Disorder (MDD)

Phase 2

Clinical Trials (1)

NCT07284667ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

Phase 2

ACP-104

Schizophrenia

Phase 2

Clinical Trials (2)

NCT00490516ACP-104 in Acutely Psychotic Subjects With Schizophrenia

Phase 2

NCT00628420Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics

Phase 1

carbetocin

Hyperphagia in Prader-Willi Syndrome

Phase 3

Clinical Trials (2)

NCT06173531Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Phase 3

NCT06420297OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

ACP-204

Lewy Body Dementia Psychosis

Phase 3

Clinical Trials (4)

NCT06194799ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

Phase 3

NCT07095465Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

Phase 3

trofinetide

Rett Syndrome

Phase 3

Clinical Trials (4)

NCT04181723Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)

Phase 3

NCT04776746Open-Label Extension Study of Trofinetide for Rett Syndrome

Phase 3

pimavanserin

Parkinson's Disease Psychosis

Phase 4

Clinical Trials (5)

NCT04809116Pimavanserin for Insomnia in Veterans With Posttraumatic Stress Disorder: Proof of Concept

Phase 4

NCT04292223Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

L. helveticus R0052 and B. longum R0175

Attention Deficit Hyperactivity Disorder

Phase 4

Clinical Trials (1)

NCT02545634Effects of a Probiotic Supplement on Symptoms of Attention Deficit Hyperactivity Disorder and Anxiety in Children

Phase 4

probiotics

Attention Deficit Hyperactivity Disorder

Phase 4

Clinical Trials (1)

NCT02035878Probiotics and the Microbiome: Clinical Intervention Trial for Anxiety and Depression

Phase 2

Interview Prep Quick Facts

Portfolio: 6 approved products, 54 clinical trials

Top TAs: Neurology, Rare Diseases

H-1B (2023): 1 approval

Publications: 32 in PubMed

SEC Filings: 2 available

Open Roles: 43 active jobs

Portfolio Health

Launch1 (17%)

Peak3 (50%)

Post-LOE2 (33%)

6 total products

Therapeutic Area Focus

Neurology

4 marketed34 pipeline

Rare Diseases

2 marketed4 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$726M40%

R&D Spend

$352M(48%)3%

Net Income

-$61M

Hiring Trend

Actively Hiring

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Rett syndrome and real-world treatment patterns of trofinetide in the United States.

Journal of medical economics

2026

PMID:42287113

Discovery of novel SSRIs for a combination-treatment with pimavanserin.

NCT00550238A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Phase 3

NCT06159673ACP-204 in Adults With Alzheimer's Disease Psychosis

Phase 2/3

NCT04279314Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome

Phase 3

NCT05357612Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

Phase 4

Bioorganic & medicinal chemistry letters

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Acadia Pharmaceuticals(ACAD)

Should You Work at Acadia Pharmaceuticals?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (2)

Key Products by Revenue

Other Products (1)

Pipeline & Clinical Trials

Recent News · Acadia Pharmaceuticals(10)

Open Jobs (43)

Executive Director, Regulatory Operations

Executive Director, Consumer Marketing

Director, Long-Term Care National Accounts

Senior Analyst, Commercial Analytics & Insights

Sr. Regional Business Leader- Great Lakes

Senior Director, Clinical Development

Director, Regulatory Affairs Advertising & Promotion

Director, External Innovation

Director, Formulation Development

Senior Manager, AI Engineering

Associate Director R&D AI Solutions & Analytics

Director, Direct Material and Manufacturing, Sourcing and Procurement

Associate Director, AI/ML Engineering

Manager, Commercial Analytics & Insights - Neuro

Senior Manager R&D Learning & Development

Director, Commercial Sourcing & Procurement

Cybersecurity Manager, AI & Security Operations

Associate Director, Regulatory Affairs Project Planning & Coordination

Associate Director Toxicology

Senior Director, Regulatory Operations

Director, R&D Sourcing and Procurement

Sr. Manager, R&D AI Solutions & Analytics

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Research Publications(10)